Correction of neutrophil chemotaxis defect in patients with gaucher disease by low‐dose enzyme replacement therapy
- 1 May 1993
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 43 (1) , 69-71
- https://doi.org/10.1002/ajh.2830430118
Abstract
We have recently described a chemotactic defect in severely afflicted Gaucher disease patients. Two of the patients were treated with low-dose intravenous enzyme replacement (Ceredase). Marked improvement in their hematological status, organomegaly, and growth was observed. In addition, their chemotactic defect and their tendency towards infections were corrected within 1 year of treatment.Keywords
This publication has 6 references indexed in Scilit:
- Gaucher's DiseaseNew England Journal of Medicine, 1991
- Enzyme replacement therapy for Gaucher diseaseBlood, 1991
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- PREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVELThe Lancet, 1989
- Isolation of Lymphocytes, Granulocytes and MacrophagesScandinavian Journal of Immunology, 1976
- LEUKOCYTE LOCOMOTION AND CHEMOTAXISThe Journal of Experimental Medicine, 1973